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To understand DNAJB6’s function in skeletal muscle and identify therapeutic targets for limb-
girdle muscular dystrophy 1D (LGMD1D).
Methods
DNAJB6 knockout (KO) myoblasts were generated with Crispr/cas9 technology, and diﬀer-
entially accumulated proteins were identiﬁed using stable isotope labeling, followed by quan-
titative mass spectrometry. Cultured KO myotubes and mouse muscle from DNAJB6b-WT or
DNAJB6b-F93L mice were analyzed using histochemistry, immunohistochemistry, and im-
munoblot. Mouse functional strength measures included forelimb grip strength and inverted
wire hang.
Results
DNAJB6 inactivation leads to the accumulation of sarcomeric proteins and hypertrophic
myotubes with an enhanced fusion index. The increased fusion in DNAJB6 KO myotubes
correlates with diminished glycogen synthase kinase-β (GSK3β) activity. In contrast,
LGMD1D mutations in DNAJB6 enhance GSK3β activation and suppress β-catenin and
NFAT3c signaling. GSK3β inhibition with lithium chloride improves muscle size and strength
in an LGMD1D preclinical mouse model.
Conclusions
Our results suggest that DNAJB6 facilitates protein quality control and negatively regulates
myogenic signaling. In addition, LGMD1D-associated DNAJB6 mutations inhibit myogenic
signaling through augmented GSK3β activity. GSK3β inhibition with lithium chloride may be
a therapeutic option in LGMD1D.
*These authors contributed equally to the manuscript.
From the Washington University School of Medicine (A.R.F., R.B., S.K.P., H.L.T., C.C.W); Department of Neurology (A.R.F., R.B., S.K.P., C.C.W), Hope Center for Neurological Diseases,
St. Louis, MO; Harbor-UCLA Medical Center (T.-F.C.), Department of Pediatrics, Division of Medical Genetics, Torrance, CA; Department of Cell Biology and Physiology (H.L.T.), Saint
Louis, MO.
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at
Neurology.org/NG.
The Article Processing Charge was funded by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
Protein chaperones, or heat shock proteins (HSPs), are in-
creasingly recognized as critical for skeletal muscle health.1
Recently, mutations in DNAJB6, an HSP40 co-chaperone,
were identiﬁed to cause limb-girdle muscular dystrophy 1D
(LGMD1D), also known as LGMD D1 DNAJB6-related,
a childhood- or adult-onset, dominantly inherited, progressive
myopathy with vacuolar and aggregate myopathology.2–5
DNAJB6 is ubiquitously transcribed and mediates proper
folding and disaggregation of proteins by HSP70.6,7 It has 2
isoforms: DNAJB6a, which localizes to the nucleus, and
DNAJB6b, which localizes diﬀusely.4,8 In skeletal muscle,
DNAJB6b localizes to the Z disc and is thought to be the
isoform responsible for disease pathogenesis of LGMD1D.4,8
LGMD1D mutations in DNAJB6 reside within the G/F do-
main, a region important for client protein handling.4,8
DNAJB6’s role in normal muscle and the pathomechanism of
disease mutations is unknown.
In addition to its role in protein homeostasis, DNAJB6 also
acts as a tumor suppressor through its interaction with glycogen
synthase kinase-β (GSK3β).9,10 GSK3β activity is dependent on
DNAJB6 chaperoning a multiprotein complex to maintain its
dephosphorylated (active) state.10 Active GSK3β negatively
regulates several myogenic signaling pathways, including
β-catenin and nuclear factor of activated T cells cytoplasmic 3
(NFATc3) signaling.10–15 DNAJB6 has also been shown to di-
rectly interact with and inhibit NFATc3 transcriptional activity
by recruiting class II histone deacetylases.16 In this study, we
explored DNAJB6’s role in skeletal muscle and its impact on
myogenesis and related signaling pathways. We also investigated
DNAJB6 disease mutation’s impact on these pathways and their
contribution to LGMD1D pathogenesis.
Methods
Generation of DNAJB6 knockout (KO)
C2C12 myoblasts
DNAJB6 KO C2C12 cells were generated using 2 guide
RNAs targeting 2 introns ofDNAJB6 to generate a 5.5-kb out-
of-frame deletion (ﬁgure e-1A, links.lww.com/NXG/A147).
We used this strategy to avoid modifying other DNAJ genes.
Clones were screened for homozygosity of the 5.5-kb deletion
via sequencing (ﬁgure e-1B). Absence of DNAJB6 protein
expression was conﬁrmed via western blot (ﬁgure 1A).
Antibodies
Antibodies used were the following: anti-rabbit GAPDH (Cell
Signaling, 2118), anti-rabbit desmin (Abcam, ab8592), anti-
rabbit DNAJB6 (Abcam, ab75196), anti-rabbit αβ-crystallin
(Enzo, ADI-SPA-223), anti-mouse hnRNPA2/B1 (Sigma,
R4653), anti-rabbit alpha-actinin (Abcam ab68167), anti-mouse
keratin 18 (Abcam, ab668), anti-rabbit GSK3β-P(ser-9) (Cell
Signaling, 9336), anti-rabbit GSK3β (Cell Signaling, 9315), anti-
goat FHL-1 (Abcam ab23937), and anti-mouse myosin (Sigma-
Aldrich,M1570). Secondary antibodies include anti-mouseHRP
(Pierce), anti-rabbit HRP (Cell Signaling), anti-goatHRP (Santa
Cruz), and anti-mouse AlexaFluor (488).
Western blot
Muscle tissues and cultured cells were homogenized using
RIPA lysis buﬀer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1% NP-40, 0.25% Na-deoxycholate and 1 mM EDTA) sup-
plemented with protease inhibitor cocktail (Sigma-Aldrich),
and lysates were centrifuged at 21380g for 10minutes. Protein
concentrations were determined using a BCA protein assay kit
(Thermo Fisher Scientiﬁc). Aliquots of lysates were solubilized
in Laemmli buﬀer, and equal amounts of proteins were separated
on 12% sodium dodecyl sulfate polyacrylamide gels. Proteins
were transferred to nitrocellulose membrane, and themembrane
was blocked with 5% nonfat dry milk in phosphate-buﬀered
saline (PBS) with 0.1% Tween-20 for 1 hour. The membrane
was then incubated with primary antibody, in 5% nonfat drymilk
overnight at 4°C, and then secondary antibody conjugated with
horseradish peroxidase. Enhanced chemiluminescence (GH
Healthcare, UK) was used for protein detection. Immunoblots
were obtained using the G:BoxChemi XT4, Genesys Version
1.1.2.0 (Syngene). Densitometry was measured with ImageJ
software (NIH).
Cell culture
HeLa cells were maintained in Dulbecco’s Modiﬁed Eagle
medium (DMEM, Gibco #11965-084), 10% fetal bovine se-
rum (FBS, Atlanta Biologicals #S10350H), and 50 μg/mL
penicillin and streptomycin (P/S, Sigma #P4333) at 37°C
with 5% CO2. C2C12 cells were maintained in proliferation
media (DMEMwith 20% FBS, 50 μg/mL P/S) and switched to
diﬀerentiation media (DMEM with 2% horse serum, 50 μg/mL
P/S) to form myotubes. Transfection of cells was performed
with Lipofectamine 2000 (Life Technologies #11668019)
according to the manufacturer’s instruction.
Plasmid construction
Mammalian constructs of DNAJB6b were cloned using site-
directed mutagenesis, digested with HindIII/XhoI, and ligated
into vector pcDNA3.1 containing a green ﬂuorescent protein
(GFP) tag. DNAJB6b F89I and P96Rmutations were generated
with the Quik Change Mutagenesis Kit (Agilent Technologies
#200517).
Glossary
CSA = cross-sectional area; GFP = green ﬂuorescent protein; GO = Gene Ontology; GSK3β = glycogen synthase kinase-β;
HSP = heat shock protein; KO = knockout; LGMD1D = limb-girdle muscular dystrophy 1D; LC-MS/MS = Liquid
chromatography with tandem mass spectrometry; NFATc3 = nuclear factor of activated T cells cytoplasmic 3; PBS =
phosphate-buﬀered saline; SILAC = stable isotope labeling with amino acids in cell culture; WT = wild type.
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Immunofluorescence
C2C12 cells were grown, stained, and imaged directly on cell
culture plastic. Cells were washed 3 times with PBS, ﬁxed in 4%
PFA for 10 minutes, permeabilized with 0.1% Triton X-100 in
PBS for 10 minutes, and then blocked with 3% BSA in PBS for
30 minutes to 1 hour at room temperature. Cells were stained
with primary antibody (anti-mouse myosin) at 4°C overnight,
followed by washing 3 times with PBS. Cells were incubated
with Alexa 488 Fluor-conjugated secondary antibody at RT
for 1 hour and mounted with Mowiol media containing 49,6-
diamidino-2-phenylindole. C2C12 diﬀerentiation experiments
were performed in triplicate. Fusion index was determined as
a ratio of nuclei number within multinucleated myosin-positive
myotubes to the total number of nuclei. Nuclei were counted
from 10 random ﬁelds taken with 10× objective equipped in
a NIKONEclipse 80i ﬂuorescencemicroscope. Myosin stained
myotubes with irregular staining pattern were counted and di-
vided by the total number of myosin-positive myotubes to
quantify the percent of myotubes with irregular myosin staining.
Electron microscopy
C2C12 cells were diﬀerentiated for 6 days, rinsed brieﬂy in
PBS, and ﬁxed immediately with Karnovsky ﬁxative at 4°C for
24 hours. Fixed myotubes were embedded in plastic and
sectioned for imaging with a JEOL JEM-1400 Plus 120 kV
Transmission Electron Microscope equipped with an AMT
XR111 high-speed 4 k × 2 k pixel phosphor-scintillated 12-bit
charge coupled device camera.
Stable isotope labeling by amino acids and
mass spectrometry
For “forward” stable isotope labeling with amino acids in cell
culture (SILAC) experiments, KO C2C12 cells were cultured
in “heavy”media in which Arg and Lys were replaced by 13C6-
Arg and 13C6,
15N2-Lys, whereas C2C12 DNAJB6 wild-type
(WT) cells were grown in “light” media containing 12C6-Arg
and 12C6,
14N2-Lys (Thermo Fisher). For “reverse” experi-
ments, DNAJB6 KOC2C12 cells were grown in “light”media
and WT C2C12 cells were grown in “heavy” media. Two
biological replicates were used for each condition. Myoblasts
were passaged 6 times to allow for suﬃcient incorporation of
label. For mass spectrometry analyses, we used the same
methodology as the one used in previous studies with minor
modiﬁcation.17,18 Brieﬂy, total cell lysate was generated using
9 M Urea in 20 mM HEPES, pH 8.0 containing protease
inhibitor and phosphatase inhibitor tablets. Equal amount
(0.3 mg) for each cell type was mixed and digested using
Lys-C and trypsin digestion protocol as described.17,18 The
peptides were loaded onto an Easy Nano-LC Q-Exactive
Orbitrap, and the peak lists were generated using Proteome
Discoverer software (Thermo Fisher Scientiﬁc).18 Only pro-
teins that were present in all biological replicates in both
forward and reverse SILAC experiments were considered for
further data analysis. Proteins were considered increased in
DNAJB6 KO C2C12 cells if there was at least a 1.5-fold
change in forward KO/WT experiments and a 0.6-fold change
in reverse WT/KO experiments. Proteins were considered
decreased in DNAJB6 KO C2C12 cells if there was at least
a 0.6-fold change in forward KO/WT experiments and a 1.5-
fold change in reverse WT/KO experiments.
Ontological analysis
All diﬀerentially expressed proteins were classiﬁed broadly
into several catalogs according to the Gene Ontology (GO)
annotation (geneontology.org). Overrepresentation analyses
of GO terms, including biological process, molecular func-
tion, and cellular component, were performed using the
ConsensusPathDB-human database system (cpdb.molgen.
mpg.de/CPDB), which is a molecular functional interaction
database. All proteins detected in SILAC experiments were
used as background for comparison. The GO level 2 and 3
categories and a p value cutoﬀ of 0.01 were selected.
Luciferase assays
C2C12 myoblasts were transfected with 20 ng Renilla control
reporter (pRL-TK) and either 1 μg of the β-catenin luciferase
reporter (TOPﬂash, Addgene plasmid #12456) or 1 μg of an
NFAT-sensitive luciferase reporter (pGL3-NFAT luciferase,
Addgene plasmid #17870).
HeLa cells were transfected with 0.5 μg of GFP control or GFP-
taggedDNAJB6b construct, 20 ng Renilla control reporter, and
either 0.5 μg of the β-catenin luciferase reporter or 0.5 μg of an
NFAT-sensitive luciferase reporter. For β-catenin luciferase
experiments, HeLa cells were treated with 20 mM lithium
chloride (LiCl) (Sigma-Aldrich 203637) for 12 hours before
measuring luminescence to stimulate β-catenin transcriptional
activity. For NFATc3 luciferase experiments, HeLa cells were
transfected with 0.5 μg of plasmid encoding NFATc3 to stim-
ulate transcriptional activity (pBS mNFATc3-EE, Addgene
plasmid #17868). Cells were lysed, and luciferase activities were
measured using the Dual-Glo luciferase kit (Promega E2920)
and a microplate luminometer (BioTek Instruments). Lysates
(75 μL) were pipetted into 96-well plates in triplicate. Data were
calculated as luciferase/Renilla signal. Fold changewas calculated
based on change fromunstimulated baseline (e.g., LiCl treated vs
untreated or NFATc3 transfected vs control transfected).
Animal studies
Animal and experimental protocols
Transgenic human-V5-DNAJB6b mice with MCK promoter
were previously generated.8 DNAJB6b-F93L mice develop
a prominent myopathy and are weak by age 3 months.8 Mice
were housed in a temperature-controlled environment with
12-hour light-dark cycles and received food and water ad
libitum. Mice were killed, and skeletal muscle was dissected.
For western blot analysis, muscle was ﬂash frozen in liquid
nitrogen and stored at −80°C.
Wire screen holding and grip test
Grip strength testing consisted of 5 separatemeasurements using
a trapeze bar attached to a force transducer that recorded peak-
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Figure 1 DNAJB6 knockout results in accumulation of sarcomeric proteins and altered myofibrillogenesis
(A) Western blot demonstrating the absence of both DNAJB6 isoforms in Crispr/Cas9-generated DNAJB6 KO C2C12myoblasts and during differentiation into
myotubes. (B) Bright-field image demonstrating normalmorphology of DNAJB6 KOmyoblasts. (C) Flowchart of forward and reverse SILAC labeling combined
with LC-MS/MS for comparative analysis of protein expression in WT and DNAJB6 KO myoblasts. (D) Quantitation overlap of the detected proteins in the 2
forward and 2 reverse SILAC labeling experiments and those that differentially accumulated in WT vs DNAJB6 KO C2C12 cells. (E) Ontological analysis of
proteins increased in DNAJB6 KOmyoblasts. (F) Ontological analysis of proteins decreased in DNAJB6 KOmyoblasts. (G)Western blot ofWT and KOmyoblasts
confirming increased levels of several proteins identified in SILAC analysis. (H) Differentiation of KO myoblasts into myotubes reveals altered myofibrillar
organization on myosin staining and electron microscopy. White arrows demonstrate Z discs in WTmyotubes with well-organized sarcomeres. Dark arrows
demonstrate Z discs in KOmyotubeswith poormyofibrillar organization. (I) Quantitation ofmyotubeswith irregularmyosin staining. Error bars represent the
standard error of 3 independent experiments. KO = knockout; LC-MS/MS = liquid chromatography with tandem mass spectrometry; SILAC = stable isotope
labeling with amino acids in cell culture; WT = wild type.
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generated force while mice were pulled backward by their tail
(Stoelting, Wood Dale, IL). The resulting measurement was
recorded, and the average of the highest 3 measurements was
determined to give the strength score. Another quantita-
tive strength measurement was performed by wire screen
holding test. Mice were placed on a grid where it stood
using all 4 limbs. Subsequently, the grid was inverted 15 cm
above a cage. Latency for the mouse to release the mesh
is recorded, and the average hanging time of 3 trials was
used.
Histochemistry
Isolated muscle was mounted using tragacanth gum
(Sigma, G1128) and quick frozen in liquid nitrogen–
cooled 2-methylbutane. Samples were stored at −80°C until
sectioning into 10-μm sections. Hematoxylin and eosin staining
was performed as previously described.19 Images were taken
with a 5-megapixel color charge coupled device (Nikon, Tokyo,
Japan), and the muscle ﬁber cross-sectional area (CSA) was
measured using ImageJ software. Two separate individuals, blin-
ded to the treatment status of mice, took photographs and
measured the CSA. Four representative images from each ani-
mal’s tibialis anterior were used to determine the average cross-
sectional area.
Lithium treatment
After oxygen exposure, mice were anesthetized with iso-
ﬂuorane and injected intraperitoneally with LiCl (250 mg/kg
body weight; Sigma-Aldrich) or dimethyl sulfoxide daily for 1
month.
Statistical analysis
Results are presented as mean and standard error of the mean.
Statistical analyses were performed using paired t tests.
Standard protocol approvals, registrations,
and patient consents
All animal experimental protocols were approved by the Ani-
mal Studies Committee of Washington University School of
Medicine.
Data availability policy
The supplementary data can be accessed via links.lww.com/
NXG/A145 and links.lww.com/NXG/A147. The authors will
share the data of this study by request from any qualiﬁed
investigator. Any data not published within the article are
available in a public repository and will be shared by request
from any qualiﬁed investigator.
Results
DNAJB6 KO myoblasts accumulate sarcomeric
proteins and form altered myofibrillar
structures
To understand DNAJB6’s role in skeletal muscle, we gener-
ated C2C12 myoblasts that lack both isoforms of DNAJB6
(DNAJB6a and DNAJB6b) using CRISPR/cas9 technology
(ﬁgure 1A). These undiﬀerentiated cells were viable and
morphologically similar to control C2C12 cells (ﬁgure 1B).
To identify diﬀerentially accumulated proteins, we performed
SILAC. SILAC experiments were conducted in duplicate,
including 2 forward (KO/WT) and 2 reverse labeling (WT/
KO) of control and DNAJB6 KO C2C12 myoblasts (ﬁgure
1C depicts the setup for SILAC-based proteomics). Using




*PDLIM3 PDZ and LIM domain protein 3 6.89
PTGIS Prostacyclin synthase 4.30
*ACTN3 Alpha-actinin-3 4.22
SERPINB9B Serpin B9 3.99
TPPP3 Tubulin polymerization-promoting
protein family member 3
3.30
FTL1 Ferritin light chain 1 3.24
NAPA Alpha-soluble NSF attachment
protein
3.16
*CRYAB Alpha-crystallin B chain 3.00
*AKAP12 Isoform 2 of A-kinase anchor
protein 12
2.92
RPL14 60S ribosomal protein L14 2.69
EXOC1 Exocyst complex component 1 2.42
*FHL1 Fourandahalf LIMdomainsprotein1 2.34
SGPL1 Sphingosine-1-phosphate lyase 1 2.26
*JUP Junction plakoglobin 2.18
PAK2 Serine/threonine protein kinase PAK 2 2.13
DNM1L Isoform 4 of dynamin-1-like protein 2.09
*DES Desmin 2.05
TUBB3 Tubulin beta-3 chain 1.97
GAA Lysosomal alpha-glucosidase 1.96
UGP2 Isoform 2 of UTP—glucose-1-
phosphate uridylyltransferase
1.95
CTSL Cathepsin L1 1.86
*DNAJB4 DnaJhomologsubfamilyBmember4 1.83
*HSPB1 IsoformBofheatshockproteinbeta-1 1.82
MVP Major vault protein 1.81
ABRACL Costars family protein ABRACL 1.80
*PDLIM1 PDZ and LIM domain protein 1 1.78
KLC2 Kinesin light chain 2 1.75
Abbreviations: KO = knockout; SILAC = stable isotope labeling with amino
acids in cell culture; WT = wild type.
Note themany sarcomeric and chaperone proteins increased in DNAJB6 KO
myoblasts (* and bold). Proteins meeting SILAC threshold of KO/WT ratio of
>1.5 and WT/KO ratio of <0.6.
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liquid chromatography with tandem mass spectrometry
analysis, we quantiﬁed 2035 proteins in the 2 forward
experiments, 2215 proteins in the 2 reverse experiments, and
a total of 2445 distinct proteins overall (ﬁgure 1D). Nearly
75% of the proteins quantiﬁed were present in both forward
and reverse experiments (ﬁgure 1D). For subsequent data
analysis, we used only proteins present in both duplicates of
the forward and reverse experiments (ﬁgure 1D). To identify
proteins that accumulate in DNAJB6 KO cells, we used 2
thresholds: a 1.5-fold change in forward KO/WT experiments
and a 0.6-fold change in reverse WT/KO experiments. Based
on these criteria, 27 proteins were identiﬁed (ﬁgure 1D, table
1). Ontological analysis of the 27 proteins increased in KO
cells identiﬁed categories such as sarcomere, Z disc, and
muscle contraction (ﬁgure 1E). Notably, these proteins in-
cluded several Z-disc proteins such as desmin, α-actinin,
FHL-1, and PDZ-Lim domain proteins 1 and 3. It also
identiﬁed the co-chaperone DNAJB4 and small HSPs
HSPB1 and HSPB5 (αβ-crystallin). Reversal of thresholds to
identify proteins decreased in DNAJB6 KO cells identiﬁed
46 proteins belonging to several ontological categories in-
cluding laminin complex and collagen catabolic process
(ﬁgure 1, D and F, table e-1, links.lww.com/NXG/A145).
Immunoblotting of lysates from control and DNAJB6 KO
Figure 2 Absence of DNAJB6 impairs GSK3β dephosphorylation and enhances myotube formation
(A) C2C12WT andDNAJB6 KOmyoblasts differentiated intomyotubes for 6 days and stained formyosin. DNAJB6 KOmyoblasts fused to form largemyotubes
with enhanced fusion index (B). Error bars represent the standard error of 3 independent experiments. (C)Western blot confirmed increased inactive GSK3β-
P(ser-9) in KO myoblasts. GSK3β-P(ser-9)/GSK3β-total ratio is given below western blot. (D) Increased β-catenin transcriptional activity in DNAJB6 KO
myoblasts compared with WT myoblasts measured by TOPFLASH luciferase assay. (E) Increased NFATc3 transcriptional activity in DNAJB6 KO myoblasts
compared with WT myoblasts. Error bars represent the standard error of at least 2 independent experiments. GSK3β = glycogen synthase kinase-β; KO =
knockout; NFATc3 = nuclear factor of activated T cells cytoplasmic 3; WT = wild type.
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myoblasts for several of these proteins conﬁrmed their ac-
cumulation (ﬁgure 1G). Skeletal muscle from LGMD1D
mice similarly demonstrates an accumulation of several of
these Z-disc proteins.8 When diﬀerentiated into myotubes,
DNAJB6 KO cells contained abnormal myoﬁbrillar struc-
tures characterized by irregular myosin immunoﬂuorescence
and disorganized sarcomere organization on electron micros-
copy (ﬁgure 1, H and I). Overall, this suggests that the absence
of DNAJB6 leads to impaired organization and accumulation of
sarcomeric proteins. These ﬁndings are similar to the myoﬁ-
brillar abnormalities noted in mouse and human LGMD1D
skeletal muscle.3,8
Figure 3 DNAJB6 disease mutation impact on GSK3β dephosphorylation and downstream signaling pathways
(A) Western blot of skeletal muscle
lysates from 3-month old LGMD1D
mutantmice (F93Lb, n = 2) vs control
(WTb, n = 2) demonstrating signifi-
cantly reduced inactive GSK3β-
P(ser-9) in mutant mice. Error bars
represent the standard error. (B)
Quantitation of western blot. Dual-
luciferase assay demonstrating re-
duced β-catenin (C) and NFATc3 (D)
transcriptional activity in HeLa cells
transfected with mutant DNAJB6b
constructs compared with unsti-
mulated controls. β-catenin tran-
scriptional activity was stimulated
via treatment with 20mM LiCl for 12
hours. NFATc3 transcriptional activ-
ity was stimulated by over-
expression of NFATc3 via transient
transection. Error bars in C and D
represent the standard error from 3
separate experiments. (E) Proposed
model for DNAJB6’s spectrum of
impact on GSK3β activation and
myogenesis. GSK3β = glycogen
synthase kinase-β; LGMD1D = limb-
girdle muscular dystrophy 1D;
NFATc3 = nuclear factor of activated
T cells cytoplasmic 3; WT =wild type.
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KO of DNAJB6 in myoblasts impairs GSK3β
activation and enhances myogenesis
When diﬀerentiated for 6 days, C2C12 myoblasts form
myotubes with a fusion index (nuclei contained in
myotubes/total nuclei) of approximately 20% (ﬁgure 2, A
and B). Surprisingly, we found that DNAJB6 KO myotubes
have an enhanced fusion index (77%) and form enlarged
myotubes (ﬁgure 2, A and B). This suggested that DNAJB6
may play a role in myogenic signaling pathways. DNAJB6 is
known to chaperone the dephosphorylation (activation) of
GSK3β, an important signaling kinase that suppresses sev-
eral myogenic signaling pathways.10,14,15,20 Compared with
WT, DNAJB6 KO myoblasts and myotubes contained in-
creased levels of phosphorylated (inactive) GSK3β-P(ser-9)
(ﬁgure 2C). This suggests that the absence of DNAJB6
is associated with impaired GSK3β-P(ser-9) de-
phosphorylation and supports DNAJB6’s proposed role in
GSK3β activation.10 GSK3β9s impact on myogenesis is
thought to be mediated through suppression of β-catenin
and NFATc3 signaling.13–15 We therefore evaluated β-cat-
enin and NFATc3 transcriptional activity using dual lucif-
erase assays. We found that both NFATc3 and β-catenin
transcriptional activity were increased in DNAJB6 KO
myoblasts (ﬁgure 2, D and E). These ﬁndings suggest that
the enlarged myotubes and enhanced fusion index resulting
from loss of DNAJB6 may be related to impaired GSK3β-
P(ser-9) dephosphorylation and increased β-catenin and
NFATc3 transcriptional activity.
LGMD1D mutations enhance GSK3β
dephosphorylation in skeletal muscle
We next investigated the impact of dominant DNAJB6
disease-causing mutations on GSK3β9s phosphorylation
state in muscle. We used skeletal muscle lysate from
3-month-old LGMD1D model mice that express a V5-
tagged DNAJB6b-F93L transgene and control mice that
express a DNAJB6b-WT transgene.8 Of interest, we found
a near complete absence of GSK3β-P(ser-9) in the
LGMD1D mice (ﬁgure 3, A and B). This suggested that
DNAJB6 disease mutations increase GSK3β de-
phosphorylation to its active state. We next evaluated the
impact of DNAJB6 mutations on myogenic signaling path-
ways downstream of GSK3β. We used a dual luciferase assay
to measure β-catenin and NFATc3 transcriptional activity in
HeLa cells transfected with GFP-tagged DNAJB6 con-
structs. We treated cells with 20 mM LiCl, a GSK3β in-
hibitor, to stimulate β-catenin transcriptional activity (ﬁgure
3C). We overexpressed NFATc3 via transient transfection of
cells to stimulate NFATc3 transcriptional activity. We found
that both β-catenin and NFATc3 transcriptional activity
were suppressed by the presence of various DNAJB6
mutants (ﬁgure 3, C and D).
These ﬁndings illustrate DNAJB6’s spectrum of impact on
GSK3β9s activity: absence of DNAJB6 is associated with
impaired dephosphorylation of GSK3β-P(ser-9), whereas
dominant disease-causing mutations in DNAJB6 enhance
dephosphorylation GSK3β-P(ser-9) to its active form
(ﬁgure 3E).
GSK3β inhibitor LiCl improves strength,muscle
mass, and histopathology in LGMD1D mice
To test the therapeutic potential of GSK3β inhibition (ﬁgure
4A), we treated 3-month-old control mice overexpressing
DNAJB6b-WT and mutant mice overexpressing DNAJB6b-
F93L with either vehicle (dimethyl sulfoxide) or LiCl via
Figure 4 GSK3β inhibition improves muscle strength in LGMD1D mice
(A) Diagram demonstrating DNAJB6’s role in chaperoning the dephosphorylation of GSK3β-P(ser-9) and treatment strategy with GSK3β inhibitor, LiCl. (B)
Functional testing (wire hang and grip strength) of 3-month-old DNAJ6b-WT and DNAJB6b-F93L mice treated daily with LiCl vs no treatment (NT). Two
independent experiments were performed for a total of 8mice per condition. Strength of DNAJB6b-F93Lmice treatedwith LiCl significantly improves over the
course of the month and reaches levels similar to DNAJB6b-WT mice. Error bars represent the standard error. *p < 0.05, **p< 0.01, ***p < 0.005. GSK3β =
glycogen synthase kinase-β; WT = wild type.
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daily intraperitoneal injection for 1 month. Results were
obtained from 4 mice per group. Two independent experi-
ments were performed for a total of 8 mice per condition.
We used a dose of 250 mg/kg body weight to mimic ther-
apeutic serum levels in humans.21,22 Skeletal muscle function
of LiCl-treated DNAJB6b-F93L mice, as measured by grip
strength and inverted wire hang test, normalized to that of
control mice over the course of the month (ﬁgure 4B). The
mass and visible size of selected muscles and muscle ﬁber
CSA were signiﬁcantly increased in DNAJB6b-F93L mice
treated with LiCl (ﬁgure 5, A-D). Despite improvements in
strength and muscle ﬁber size, western blot analyses of
skeletal muscle lysates demonstrated no change in accu-
mulated sarcomeric proteins or RNA-binding proteins seen
with DNAJB6 mutations (ﬁgure 5E).
Discussion
This study demonstrates that DNAJB6’s role in skeletal
muscle involves not only sarcomeric protein quality con-
trol but also suppression of myogenic signaling pathways
important for myoblast diﬀerentiation, myotube fusion,
skeletal muscle hypertrophy, and regeneration. Many
other skeletal muscle chaperones also have dual roles in
protein quality control and modulation of signaling path-
ways. The co-chaperone BAG3 facilitates autophagic sorting
of damaged ﬁlamin to lysosomes while also engaging in
YAP/TAZ mechanotransduction signaling.23 αβ-crystallin not
only functions as a desmin chaperone at the Z disc but also
modulates NF-κβ and TGF-β2 signaling.24,25 HSP70 and
HSP90 not only play key roles inmyoﬁbrillogenesis but also act
Figure 5 GSK3β inhibition improves muscle size in LGMD1D mice
(A) Mass of selected muscles after 1 month of treatment. Note visible difference in the size of F93L muscles treated with LiCl. (B) H&E staining of TA from
LiCl treated or untreated F93L mice illustrating increased muscle fiber size and reduced fiber size variability. Two representative examples are provided
from the tibialis anterior. (C) Quantitation of fiber CSA profile demonstrates an overall increase in the muscle fiber size after LiCl treatment in F93L mice
and no change in LiCl-treated control mice. (D) Average muscle fiber cross-sectional area of LiCl-treated F93L mice significantly improves but does not
reach control levels. LiCl does not alter the muscle fiber size of control mice. Error bars from A and D represent the standard error. (E) Western blot of
skeletal muscle lysates in LiCl-treated and untreated mice illustrates no improvement in accumulated sarcomeric proteins or RNA-binding proteins in
F93L mice. WT = wild type.
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as circulating cachexins by activating the p38β-MAPK-C/EBPβ
catabolic signaling pathway.26 Although these dual functions
may initially seem unrelated, regulation of protein synthesis is
central to both these stress signaling pathways and maintaining
balanced protein homeostasis. It is therefore not surprising to
ﬁnd chaperones that coordinate protein quality control with
signaling pathways regulating protein synthesis.
Our comparisons between DNAJB6 KO and dominant
LGMD1Dmodels facilitated many interesting observations of
DNAJB6’s dual roles in skeletal muscle. For instance, KO of
DNAJB6 in myoblasts and myotubes recapitulated the myo-
ﬁbrillar disorganization and accumulation of sarcomeric pro-
teins seen in LGMD1D patients and animal models.3,8 In
general, protein aggregation in myopathies may occur from
mutations causing a protein itself to misfold and aggregate
(e.g., desmin) or from mutations in protein quality control
machinery (e.g., αβ-crystallin) causing other proteins to
aggregate (desmin). With DNAJB6, the absence of sarco-
meric chaperone activity could explain the altered myoﬁ-
brillar assembly and accumulation of sarcomeric proteins in
KO cells. Other DNAJB6 KO models have similarly
resulted in aggregation of client proteins.27,28 Because
LGMD1D is not due to a KO or loss of DNAJB6, one could
speculate that the vacuolar and aggregate myopathology
seen with disease mutations results from a dominant neg-
ative eﬀect on DNAJB6’s sarcomeric chaperone activities.
Lending support to this theory, mutations in VCP, BAG3,
and CRYAB are also thought to cause myopathies with
vacuoles and aggregates from a dominant negative
mechanism.29–31
However, several ﬁndings in this study do not ﬁt this theory.
Speciﬁcally, dominant mutations and absence of DNAJB6 had
opposite eﬀects on GSK3β phosphorylation status and down-
streammyogenic signaling pathways.We found an increased size
of DNAJB6 KO myotubes owing to an enhanced fusion index.
This may be related to impaired dephosphorylation of GSK3β-
P(ser-9) and derepression of downstream myogenic signaling
pathways such as β-catenin and NFATc3.9–12,32 Contrary to KO
cells, dominant DNAJB6 mutations were associated with an
enhanced dephosphorylation of GSK3β-P(ser-9) and sup-
pressed β-catenin andNFATc3 transcriptional activity. Although
DNAJB6 is known to chaperone the dephosphorylation of
GSK3β-P(ser-9) to maintain it in an active state, the exact
mechanism linking DNAJB6 disease mutations with enhanced
GSK3β-P(ser-9) dephosphorylation is not clear. One could
speculate that it may be related to a gain of function from in-
creased stability of the mutant DNAJB6 protein; however, fur-
ther studies are needed.4,8
As DNAJB6 appears to have multiple functions within skeletal
muscle, it is not surprising that mutations may cause disease
through multiple mechanisms. LiCl is well suited to address
alterations in both GSK3β signaling and protein aggregation.
It acts as a competitive inhibitor of the adenosine tri-
phosphate–magnesium-dependent catalytic activity of
GSK3β and may also act indirectly through enhanced phos-
phorylation of GSK3β.33 Although GSK3β activity suppresses
myogenesis and blunts skeletal muscle regeneration, it has
also been linked to formation of aggregates in several dis-
orders, making GSK3β inhibition a good strategy for
LGMD1D treatment.34,35 LiCl also stimulates autophagy in-
dependent of GSK3β, which may beneﬁt LGMD1D further.36
Given LiCl’s dual impact on GSK3β and autophagy, many
have used it to treat in vivo models of neurologic disorders
with protein aggregate pathology and GSK3β dysfunction,
such as Huntington disease, Alzheimer disease, SOD1
amyotrophic lateral sclerosis, Parkinson disease, and inclusion
body myositis.33–35,37–40 In addition to showing therapeutic
eﬃcacy in these animal models, LiCl improved biochemical
markers of disease and histopathologic evidence of
aggregates.34,37–40 These previous studies raise the possibility
that the signiﬁcant improvement of LGMD1D mice treated
with LiCl was due to enhanced autophagy and clearance of
accumulated sarcomeric proteins. Of interest, the accumu-
lations of sarcomeric and RNA binding proteins in mutant
mouse muscle were not altered by LiCl treatment (ﬁgure
5E). This lack of improvement may simply be due to
pathologic changes lagging behind functional improve-
ments. However, it may actually suggest that LGMD1D
pathogenesis is due not only to DNAJB6 dysfunction
in protein quality control but also to GSK3β-related sig-
naling pathways. Further studies are required to clarify,
however, that LiCl may be an ideal therapeutic option for
LGMD1D.
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